Valeur202020212022202320242025TTMFlux de trésorerie liés aux activités d'investissement-58.8 M-175.34 M109.59 M87.36 M104.07 M14.04 M16.73 MFlux de trésorerie liés aux activités de financement465.28 M211.5 M81.84 M5 M51.48 M53.05 M52.98 MFlux de trésorerie disponible-177.98 M-215.71 M-216.22 M-124.37 M-104.08 M-88.63 M-83.35 M
Inovio Pharmaceuticals, Inc. - Common Stock
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development.